Afya Ltd.

How big is Afya Ltd.?

As of Jun 18, Afya Ltd. has a market capitalization of 1,733.87 million, with net sales of 612.60 million and net profit of 123.88 million over the latest four quarters. Shareholder's funds are 691.17 million and total assets are 1,429.23 million as of Dec 24.

As of Jun 18, Afya Ltd. has a market capitalization of 1,733.87 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 612.60 million, while the sum of Net Profit for the same period is 123.88 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 691.17 million and Total Assets at 1,429.23 million.

What does Afya Ltd. do?

Afya Ltd. is a Brazil-based medical education group focused on providing a physician-centric ecosystem for lifelong medical learners. As of March 2025, it reported net sales of $160 million and a net profit of $44 million, with a market cap of approximately $1.73 billion.

Overview: <BR>Afya Ltd. is a Brazil-based medical education group that operates within the Tour, Travel Related Services industry, delivering a physician-centric ecosystem for lifelong medical learners.<BR><BR>Financial Snapshot: <BR>Net Sales: 160 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 44 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,733.87 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.25 <BR>Return on Equity: 16.12% <BR>Price to Book: 2.26<BR><BR>Contact Details: <BR>Address: Alameda Oscar Niemeyer, No 119, Sala 504 Vila Da Serra Nova Lima None : 00000 <BR>Tel: 55 31 35157500 <BR>Website: https://afya.com.br/

Should I buy, sell or hold Afya Ltd.?

Is Afya Ltd. overvalued or undervalued?

As of July 7, 2025, Afya Ltd. is considered undervalued with a valuation grade upgrade to attractive, supported by favorable P/E, PEG, and EV to EBITDA ratios, despite mixed stock performance showing a 1-year return of -2.86% compared to the S&P 500's 17.14%, and a 3-year return of 14.24% versus the S&P 500's 70.41%.

As of 7 July 2025, the valuation grade for Afya Ltd. moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued, supported by a P/E ratio of 13, a PEG ratio of 0.68, and an EV to EBITDA ratio of 7.15, which are favorable compared to its peers. For instance, Agiliti, Inc. has a P/E ratio of -69.98, while European Wax Center, Inc. has a P/E of 16.93, highlighting Afya's relative attractiveness in the market.<BR><BR>Despite the positive valuation indicators, Afya's recent stock performance shows mixed results compared to the S&P 500, with a 1-year return of -2.86% against the benchmark's 17.14%. However, over a 3-year period, Afya has returned 14.24%, while the S&P 500 returned 70.41%, suggesting that while the stock may be undervalued, it has underperformed the broader market in the longer term.

Is Afya Ltd. technically bullish or bearish?

As of September 8, 2025, Afya Ltd. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but lagging behind in year-to-date and one-year returns.

As of 8 September 2025, the technical trend for Afya Ltd. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD remains bearish. The Bollinger Bands and moving averages are both signaling mildly bearish trends on a weekly basis. The KST and Dow Theory are bearish and mildly bearish, respectively, on a monthly basis. The OBV shows a mildly bullish trend weekly but is mildly bearish monthly. <BR><BR>In terms of performance, Afya Ltd. has outperformed the S&P 500 over the past week and month, with returns of 1.59% and 4.66% compared to 1.05% and 2.33% for the index, respectively. However, the year-to-date and one-year returns are negative at 0.50% and -2.86%, significantly lagging behind the S&P 500's 12.22% and 17.14%. Overall, the current technical stance is mildly bearish, with mixed signals across different indicators.